WIC
LGND icon

Woodmont Investment Counsel’s Ligand Pharmaceuticals LGND Stock Holding History

Woodmont Investment Counsel’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-29
Closed -$2K – 431
2016
Q3 		$2K Buy
+29
New +$2.13K ﹤0.01% 650

Other funds holding LGND

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Woodmont Investment Counsel's LGND Position: Q4 2016 in Review

Woodmont Investment Counsel sold out of Ligand Pharmaceuticals (LGND) in Q4 2016, closing a stake of 29 shares — an estimated $2K sold.

Woodmont Investment Counsel first reported a position in LGND in Q3 2016 and held it in 1 quarter. The position peaked at $2K in Q3 2016. 270 funds tracked by Wall St. Rank hold LGND as of Q4 2016.

  • Woodmont Investment Counsel reported no remaining Ligand Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Woodmont Investment Counsel sold 29 Ligand Pharmaceuticals shares in Q4 2016, an estimated $2K.
  • Woodmont Investment Counsel first reported a position in Ligand Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Woodmont Investment Counsel's Ligand Pharmaceuticals position peaked at $2K in Q3 2016.
  • 270 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2016.

Based on Woodmont Investment Counsel's 13F filing for Q4 2016, filed 13 Feb 2017.